ARNI与RAS阻断剂在老年HFrEF患者中的疗效比较
本研究利用美国Medicare索赔数据(2014-2017),在≥65岁HFrEF患者中比较ARNI与RAS阻断剂单药治疗的有效性。主要复合终点为心衰恶化或全因死亡,ARNI组风险较低(合并HR 0.84,95%CI 0.80-0.89),1年RMST差异为9天(95%CI 6-12) favoring ARNI。
要点
- 在老年HFrEF患者中,ARNI较RAS阻断剂单药治疗降低心衰恶化或全因死亡复合终点风险。
- 转换队列中ARNI获益更明显(HR 0.79),起始队列HR 0.92。
- ARNI组1年受限平均生存时间延长9天(95%CI 6-12)。
核心结论
- 在≥65岁HFrEF患者中,ARNI治疗与较低的复合有效性终点风险相关。
研究设计与样本
- 设置起始队列(ARNI或RAS阻断剂单药起始)和转换队列(从ACEI转换为ARNI或ARB),分别分析后固定效应合并。
- 采用倾向评分精细分层加权调整71项暴露前特征,计算Cox回归HR和1年受限平均生存时间(RMST)差异。
主要发现
- ARNI vs RAS阻断剂单药的调整HR:起始队列0.92(95%CI 0.84-1.00),转换队列0.79(95%CI 0.74-0.85),合并估计0.84(95%CI 0.80-0.89)。
- 调整后1年RMST差异:起始队列4天(95%CI -1至9),转换队列12天(95%CI 8至17),合并估计9天(95%CI 6至12), favoring ARNI。
临床怎么用
- 对于≥65岁HFrEF患者,ARNI可作为优于RAS阻断剂单药的治疗选择,尤其适用于从ACEI转换的患者。
局限性
- 研究基于美国Medicare索赔数据,结果可能受未测量混杂因素影响。
- 起始队列的HR置信区间上限为1.00,获益不确定性较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness of angiotensin receptor-neprilysin inhibitor (ARNI) versus renin-angiotensin system (RAS) blockade alone in older adults with heart failure with reduced ejection fraction (HFrEF). METHODS: We conducted a cohort study using US Medicare fee-for-service claims data (2014-2017). Patients with HFrEF ≥65 years were identified in two cohorts: (1) initiators of ARNI or RAS blockade alone (ACE inhibitor, ACEI; or angiotensin receptor blocker, ARB) and (2) switchers from an ACEI to either ARNI or ARB. HR with 95% CI from Cox proportional hazard regression and 1-year restricted mean survival time (RMST) difference with 95% CI were calculated for a composite outcome of time to first worsening heart failure event or all-cause mortality after adjustment for 71 pre-exposure characteristics through propensity score fine-stratification weighting. All analyses of initiator and switcher cohorts were conducted separately and then combined using fixed effects. RESULTS: 51 208 patients with a mean age of 76 years were included, with 16 193 in the ARNI group. Adjusted HRs comparing ARNI with RAS blockade alone were 0.92 (95% CI 0.84 to 1.00) among initiators and 0.79 (95% CI 0.74 to 0.85) among switchers, with a combined estimate of 0.84 (95% CI 0.80 to 0.89). Adjusted 1-year RMST difference (95% CI) was 4 days in the initiator cohort (-1 to 9) and 12 days (8 to 17) in the switcher cohort, resulting in a pooled estimate of 9 days (6 to 12) favouring ARNI. CONCLUSION: ARNI treatment was associated with lower risk of a composite effectiveness endpoint compared with RAS blockade alone in older adults with HFrEF.
引用
- Desai RJ, Patorno E, Vaduganathan M, et al. Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. Heart. 2021. PMID: 34088766. doi:10.1136/heartjnl-2021-319405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。